title: Cyclooxygenase-2 plays an essential part in cardioprotection of delayed phase of recombinant human erythropoietin preconditioning in rats.
abstract: OBJECTIVE
  To study the cardioprotection of recombinant human erythropoietin (rhEPO) preconditioning (EPC) and to investigate the role and possible mechanism of cyclooxygenase (COX)-2 in the delayed phase of EPC.
  
  
  METHODS
  In phase 1, myocardial ischaemia reperfusion (I-R) rat model was established by 30 minutes ligation of left descending coronary and three hours of reperfusion. Rats were given 0.9% saline solution or rhEPO 24 hours before I-R protocol. COX-2 selective inhibitor celecoxib was given for further investigation of the cardioprotection of EPC. At the end of I-R protocol, infarct sizes were measured and ultrastructural organisations were studied. In phase 2, myocardial COX-2 mRNA expressions and prostaglandins (PGs) contents were studied in different groups after euthanasia.
  
  
  RESULTS
  It was found that EPC could elicit potent cardioprotection against I-R injury, shown by reduction of infarct size and improvement of ultrastructural organisation; whereas administration of celecoxib resulted in complete loss of this protection. EPC resulted in robust increase in COX-2 mRNA and PGs levels that were also abrogated by celecoxib.
  
  
  CONCLUSIONS
  COX-2 plays an essential part in cardioprotection of the delayed phase of EPC in rats, which might be related to actions of PGE(2) or PGI(2), or both.
authors.affiliation: Department of Anaesthesiology, Jinling Hospital, Nanjing, China.
authors.forename: X
authors.initials: X
authors.lastname: Liu
authors.forename: Z
authors.initials: Z
authors.lastname: Zhou
authors.forename: X
authors.initials: X
authors.lastname: Feng
authors.forename: Z
authors.initials: Z
authors.lastname: Jia
authors.forename: Y
authors.initials: Y
authors.lastname: Jin
authors.forename: J
authors.initials: J
authors.lastname: Xu
mesh_terms: D000818:Animals; D000068579:Celecoxib; D051546:Cyclooxygenase 2 / Q000502:physiology*; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D004921:Erythropoietin / Q000627:therapeutic use*; D019157:Ischemic Preconditioning, Myocardial; D008026:Ligation; D008297:Male; D017202:Myocardial Ischemia / Q000628:therapy*; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D011720:Pyrazoles / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D011994:Recombinant Proteins; D013449:Sulfonamides; D004921:Erythropoietin; D051546:Cyclooxygenase 2; D000068579:Celecoxib